Miebo Shortage: What Providers and Prescribers Need to Know in 2026

Miebo (perfluorohexyloctane ophthalmic solution) has rapidly become an important tool in the management of evaporative dry eye disease, particularly for patients with meibomian gland dysfunction (MGD). However, prescribers are encountering access challenges that require clinical and administrative navigation. This guide provides a comprehensive 2026 update on Miebo's formulary status, prior authorization strategies, patient assistance programs, and when to consider clinical alternatives.

Is There a Miebo Manufacturing Shortage?

No. As of 2026, Miebo is not listed on the FDA drug shortage database or the ASHP shortage list. Bausch + Lomb reported $172 million in Miebo sales for 2024 — well above initial projections of $95 million — and the company projects sales to exceed $500 million annually. There is no evidence of production constraints.

Patient access challenges are therefore not supply-side but demand-side: stocking decisions at the retail pharmacy level, insurance formulary placement, and prior authorization (PA) requirements. Understanding this distinction helps target the right interventions.

Miebo's 2026 Formulary Landscape

Coverage has grown substantially since launch:

• Commercial insurance: Approximately 75% of commercial plans cover Miebo as of January 2025. Some require PA or step therapy (prior trial of artificial tears).
• Medicare Part D: Approximately 65% of Medicare Part D plans cover Miebo. About 70% cover it without additional steps required.
• Medicaid: Almost all Medicaid plans cover Miebo, though state-specific PA requirements vary.

When prescribing Miebo, document the clinical rationale clearly — particularly the presence of evaporative DED and meibomian gland dysfunction — as this supports PA submissions.

Managing Prior Authorization for Miebo

Prior authorization is one of the most common barriers prescribers encounter with Miebo. Here are best practices for navigating PA successfully:

1. Document the DED subtype: Explicitly document evaporative DED and/or MGD in the clinical note. Include meibography findings, tear film breakup time, and corneal staining if available.
2. Document prior therapy failure: Many plans require step therapy (artificial tears, then prescription drops). Document previous OTC and Rx treatments tried and their outcome.
3. Use BlinkRx for PA support: E-prescribing to BlinkRx (Boise, Idaho) routes the prescription through a system that proactively handles PA and applies savings programs. BlinkRx's team of pharmacists and technicians will contact your office if additional documentation is needed.
4. Submit a Letter of Medical Necessity: For complex cases, prepare an LMN that explains why Miebo is specifically indicated for this patient's subtype of DED and why alternatives are insufficient.

Patient Assistance and Savings Programs

Help your patients navigate Miebo costs with these programs:

• MIEBO MySavings Copay Card: Eligible commercially insured patients may pay as little as $0 per fill. Card is available at MIEBO.CopaySavingsProgram.com. Not valid for Medicare, Medicaid, TRICARE, or other government programs.
• BlinkRx digital pharmacy: Automatically applies copay savings. Available nationwide. Eligible Medicare patients may access product trials through BlinkRx.
• Formulary exception requests: For non-covered patients, a formulary exception supported by clinical documentation can sometimes achieve coverage.
• GoodRx/SingleCare discount cards: Cash-pay patients can use discount programs to reduce cost to approximately $778–$810 per fill.

Clinical Alternatives When Miebo Is Not Accessible

If Miebo is not accessible for a patient, consider the following evidence-based alternatives:

• For evaporative DED/MGD: Warm compresses, lid hygiene, lipid-based artificial tears (e.g., Systane Complete PF, Refresh Optive Mega-3), and omega-3 supplementation may partially address tear evaporation while insurance or access issues are resolved.
• For aqueous-deficient/inflammatory DED: Cyclosporine (Restasis/generic, Cequa, Vevye) or lifitegrast (Xiidra) remain first-line options with strong evidence.
• For patients who can't tolerate any eye drops: Tyrvaya (varenicline nasal spray) offers a completely non-topical ocular approach.

How medfinder for Providers Can Help

If your patients are being turned away at retail pharmacies, medfinder for Providers offers real-time pharmacy stock data so your staff can route prescriptions to pharmacies that currently have Miebo in stock. This reduces the back-and-forth for your team and your patients.

The Bottom Line for Prescribers

Miebo has a strong and growing evidence base for evaporative DED. The current access barriers are administrative, not clinical or supply-related. Proactive PA documentation, use of BlinkRx, and patient savings programs will resolve access for the majority of your patients. For the remainder, document clearly and pursue appeals or formulary exceptions.